| pubmed-article:11488308 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11488308 | lifeskim:mentions | umls-concept:C0041296 | lld:lifeskim |
| pubmed-article:11488308 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:11488308 | lifeskim:mentions | umls-concept:C0123759 | lld:lifeskim |
| pubmed-article:11488308 | lifeskim:mentions | umls-concept:C1522673 | lld:lifeskim |
| pubmed-article:11488308 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:11488308 | pubmed:dateCreated | 2001-8-7 | lld:pubmed |
| pubmed-article:11488308 | pubmed:abstractText | Interleukin-12 (IL-12) proved to be an effective and successful adjuvant to a standard antituberculotic medication in a patient suffering from progressive clinical tuberculosis (TB). IL-12 is a potent enhancer of interferon-gamma production which is necessary for killing intracellular bacteria like mycobacteria. This patient's TB was progressive, although sensitivity to first-line antituberculotics was proven and medication was given as directly observed therapy over more than 8 months. The 3-month adjuvant therapy with IL-12 significantly and convincingly improved results. It is believed that this case, the first in the literature to describe adjuvant interleukin-12 therapy in tuberculosis, strongly encourages the study of adjuvant interleukin-12 therapy on a more systematic basis. | lld:pubmed |
| pubmed-article:11488308 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11488308 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11488308 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11488308 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11488308 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11488308 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11488308 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11488308 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11488308 | pubmed:month | May | lld:pubmed |
| pubmed-article:11488308 | pubmed:issn | 0903-1936 | lld:pubmed |
| pubmed-article:11488308 | pubmed:author | pubmed-author:SchlaakMM | lld:pubmed |
| pubmed-article:11488308 | pubmed:author | pubmed-author:ErnstMM | lld:pubmed |
| pubmed-article:11488308 | pubmed:author | pubmed-author:EntzianPP | lld:pubmed |
| pubmed-article:11488308 | pubmed:author | pubmed-author:GreinertUU | lld:pubmed |
| pubmed-article:11488308 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11488308 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:11488308 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11488308 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11488308 | pubmed:pagination | 1049-51 | lld:pubmed |
| pubmed-article:11488308 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:11488308 | pubmed:meshHeading | pubmed-meshheading:11488308... | lld:pubmed |
| pubmed-article:11488308 | pubmed:meshHeading | pubmed-meshheading:11488308... | lld:pubmed |
| pubmed-article:11488308 | pubmed:meshHeading | pubmed-meshheading:11488308... | lld:pubmed |
| pubmed-article:11488308 | pubmed:meshHeading | pubmed-meshheading:11488308... | lld:pubmed |
| pubmed-article:11488308 | pubmed:meshHeading | pubmed-meshheading:11488308... | lld:pubmed |
| pubmed-article:11488308 | pubmed:meshHeading | pubmed-meshheading:11488308... | lld:pubmed |
| pubmed-article:11488308 | pubmed:meshHeading | pubmed-meshheading:11488308... | lld:pubmed |
| pubmed-article:11488308 | pubmed:meshHeading | pubmed-meshheading:11488308... | lld:pubmed |
| pubmed-article:11488308 | pubmed:meshHeading | pubmed-meshheading:11488308... | lld:pubmed |
| pubmed-article:11488308 | pubmed:meshHeading | pubmed-meshheading:11488308... | lld:pubmed |
| pubmed-article:11488308 | pubmed:meshHeading | pubmed-meshheading:11488308... | lld:pubmed |
| pubmed-article:11488308 | pubmed:meshHeading | pubmed-meshheading:11488308... | lld:pubmed |
| pubmed-article:11488308 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11488308 | pubmed:articleTitle | Interleukin-12 as successful adjuvant in tuberculosis treatment. | lld:pubmed |
| pubmed-article:11488308 | pubmed:affiliation | Dept Internal Medicine, Research Centre Borstel, Germany. | lld:pubmed |
| pubmed-article:11488308 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11488308 | pubmed:publicationType | Case Reports | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11488308 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11488308 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11488308 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11488308 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11488308 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11488308 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11488308 | lld:pubmed |
